A 6-month hiatus in GLP-1 drug use was linked with an increased risk of major adverse cardiovascular events in patients with type 2 diabetes compared with continued use, according to a target trial emulation. (BMJ Medicine)
Could a microneedle vaccine patch be the future of GLP-1 drug delivery? (Endpoints News)
Routine IGF-1 screening in all patients with poorly controlled type 2 diabetes offers “limited diagnostic yield” and should be reserved for patients with acromegaly features, said researchers of a cross-sectional study. (Endocrinology, Diabetes & Metabolism)
From sleep apnea to kidney disease, the Washington Post examined 13 possible ways that GLP-1 receptor agonists can benefit patients.
The investigational, subcutaneous monoclonal antibody elegrobart led to greater reductions in proptosis versus placebo in a phase III trial of active thyroid eye disease; 51% of patients also had complete resolution of diplopia, developer Viridian Therapeutics announced.
Corcept’s MOMENTUM trial showed that 27.3% of patients with resistant hypertension had hypercortisolism; the findings are in line with those from the CATALYST trial, which found hypercortisolism in 23.8% of patients with difficult-to-control type 2 diabetes.
The World Obesity Federation and other global organizations said that diet and exercise should remain a central part of the global GLP-1 drug rollout, warning that “reliance on medication alone may lead to poor long-term outcomes.”
Renowned diabetes researcher Jesse Roth, MD, best known for his research on cell surface receptors, died at age 91. (New York Times)
Switching from dulaglutide (Trulicity) to tirzepatide (Mounjaro) led to a measurable boost in emotional well-being for people with type 2 diabetes, according to an analysis of the SURPASS-SWITCH trial. (Annals of Internal Medicine)
The American Diabetes Association released the abridged version of its 2026 Standards of Care in Diabetes.
Treatment with the monoclonal antibody burosumab led to improved growth outcomes over 3.3 years in children and adolescents with X-linked hypophosphatemia, interim data from the APEX trial suggested. (Journal of Clinical Endocrinology & Metabolism)
Teva Pharmaceutical’s biosimilar denosumab-adet (Ponlimsi) is now FDA approved across all indications of the reference product, Prolia, including several debilitating bone conditions.
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/120579
Author :
Publish date : 2026-03-31 18:41:00
Copyright for syndicated content belongs to the linked Source.
